Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

se 3 studies (D9901 and D9902A), Dendreon would expect to achieve the pre-specified criterion for significance and would amend the BLA submission with the FDA based on these interim results.

"The amendment of the SPA allows us to accelerate the expected timing of our final results by a year while maintaining comparable power for the study," said Mitchell H. Gold, president and chief executive officer of Dendreon. "Our commitment to helping patients with prostate cancer is unwavering, and we remain focused on providing the necessary data to the FDA as quickly as possible to enable us to bring PROVENGE to the men in need of a new treatment option."

Conference Call Information

Dendreon will host a conference call tomorrow at 8:00 a.m. PT, 11:00 a.m. ET. To access the live call, dial 1-877-548-7901 (domestic) or +1-719-325-4844 (international). The call will also be audio webcast and will be available from the Company's website at http://www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 5074038. The replay will be available from 7:30 pm ET on Thursday, March 13 until 11:59 pm ET on Saturday, March 15. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About IMPACT Study Design

The IMPACT trial is a randomized, double blind, placebo controlled Phase 3 study, which enrolled just over 500 men with metastatic, androgen independent prostate cancer with a primary endpoint of overall survival.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than o
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... N.C. , May 29, 2015 ... affairs function into roles involving clinical development, regulatory ... its responsibilities have grown, Medical Affairs has faced ... as a global group. And while its importance ... it challenging to identify strong performance metrics to ...
(Date:5/29/2015)... , May 29, 2015 In recent ... the availability of Big Data that can generate valuable ... come with utilizing Big Data have caused the biopharmaceutical ... other industries. According to a recent ... participants already have a Big Data team or function ...
(Date:5/29/2015)... , May 29, 2015 ... company, today announces that an abstract on the latest ... inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, ... BerGenBio, has been published in conjunction with the 2015 ... Chicago , May 29 - June ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... Corp.,(TSX, FSE: "HBP") today announced financial results for the first quarter,of ... - Subsequent to the first quarter, the Company ... of common shares, subject to closing, ... Segal remaining the Company,s Chief Executive ...
... two important surgical tools: Baxter,s ... human thrombin and Pfizer,s GELFOAM, ... announced the Food and Drug Administration approval of,GELFOAM(R) Plus ... Plus is the only available hemostasis kit that contains,Pfizer,s ...
... Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for ... ... 17 ,Eli Lilly and Company (NYSE: LLY ) and ... have entered into a licensing and,development agreement granting Lilly exclusive ...
Cached Biology Technology:Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 2Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 2Lilly and BioMS Medical Announce Global Licensing and Development Agreement 3Lilly and BioMS Medical Announce Global Licensing and Development Agreement 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 5Lilly and BioMS Medical Announce Global Licensing and Development Agreement 6
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... described fossil whales---a pregnant female and a male of the ... insights into how whales made the transition from land to ... 2000 and 2004 and studied at the University of Michigan, ... online journal PLoS . U-M paleontologist Philip Gingerich, ...
... In 2005, a woman who had trouble sleeping asked ... sleep disorders specialist at the Mayo Clinic campus in ... interrupts sleep because of unpleasant sensations in the legs ... relieved by movement. Restless legs syndrome affects ...
... State University already have shown that gardening can offer enough ... In research to be published in February in the journal ... health benefits of gardening is keeping older hands strong and ... older adults who are gardeners have better hand strength and ...
Cached Biology News:Early whales gave birth on land, fossil find reveals 2Mayo Clinic researchers suspect a novel gene is causing restless legs syndrome in a large family 2Gardening gives older adults benefits like hand strength and self-esteem 2